LB Pharmaceuticals Inc.

We are developing a novel, patented analogue of amisulpride (AMI) for the US market to treat schizophrenia. AMI is available in Europe but not the US

  • Stage Product In Development
  • Industry Biotechnology
  • Location New York, NY, US
  • Currency USD
  • Founded September 2015
  • Employees 4
  • Incorporation Type C-corp
  • Website LBPharma.us

Company Summary

The market for schizophrenia in the US is made up of > 3m patients and 14+ approved drugs (most generic). In Europe the two most potent drugs for this indication are clozapine and amisulpride (AMI). AMI generates more than 2 million Rx/year in the EU. In some countries such as the UK, AMI makes up > 15% of all prescriptions written. AMI has never been developed or approved in the US. We have invented LB-102; an improved version of AMI for the US.

Team

Advisors

  • Vincent Grattan
    Unconfirmed
    Marc Kirshbaum
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free